AN2 Therapeutics, Inc. ANTX 深 沪
等待开盘 05-26 09:30:00 美东时间
4.85
-0.040
-0.82%
华盛通- 最 高5.235
- 今 开4.89
- 成交量 73.15万股
- 最 低 4.67
- 昨 收 4.89
- 总市值 1.75亿
- 52周最高 6.9099
- 市盈率 静 --
- 换手率 2.03%
- 52周最低 1.00
- 委 比 -79.51%
- 总股本 3601.62万
- 历史最高 23.58
- 量 比 4.59
- 振 幅 11.55%
- 历史最低 0.87
- 每 手 1
- 风险率 1.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
05-15 04:35
AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2
03-31 19:07
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from
03-18 04:07
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.
03-11 21:52
美股牛股 | 医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%
医药股齐升！Xenon制药飙升近50%，癫痫新药临床试验获重大突破；HIMS大涨40%，获诺和诺德授权销售其减肥药；QURE大涨26%，FDA疫苗负责人将离职，有分析称监管政策或转向灵活>>
03-10 16:46
AN2 Therapeutics Plans Phase 2 Trial Of Oral Epetraborole In Polycythemia Vera; Study To Begin Q3 2026 With Potential For Data Readouts As Early As Q4 And Throughout 2027
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027AN2 to host webcast on Wednesday,
03-04 05:01
The FDA Clears Oregon Health & Science University's Investigational New Drug Application To Proceed With Investigator-Initiated Trial Of AN2 Therapeutics' Epetraborole For Mycobacterium Abscessus Lung Disease, Patient Enrollment To Start In Q1 2026
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapiesLed by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop, trial will focus on early-stage,
01-12 20:10
